A 32-year-old patient with HIV is enrolled in a clinical
trial for an experimental therapy aimed at making their T cells resistant to
viral entry. The therapy targets the CCR5 co-receptor, which HIV uses to infect
T cells. The research team must decide how to deliver the zinc finger nucleases
(ZFNs) to safely and effectively disrupt CCR5 in the patient’s cells.

Which delivery strategy was used in this type of
CCR5-targeted ZFN therapy?

Question

A 32-year-old patient with HIV is enrolled in a clinical
trial for an experimental therapy aimed at making their T cells resistant to
viral entry. The therapy targets the CCR5 co-receptor, which HIV uses to infect
T cells. The research team must decide how to deliver the zinc finger nucleases
(ZFNs) to safely and effectively disrupt CCR5 in the patient’s cells.

Which delivery strategy was used in this type of
CCR5-targeted ZFN therapy?

Accepted Answer

Ex
vivo treatment of the patient’s T cells with ZFNs, followed by reinfusion of
the edited cells

Answer

Direct
intravenous administration of ZFN proteins to target the patient’s T cells

Answer

Intravenous
delivery of a viral vector encoding ZFNs directly to the patient’s T cells

Answer

In
vivo treatment of the patient’s T cells with ZFNs, followed by reinfusion of
the edited cells

Crowdly

A 32-year-old patient with HIV is enrolled in a clinical trial for an experimen...

Want instant access to all verified answers on learning.monash.edu?